
    
      After complete islet graft loss is determined, patient's maintenance immunosuppression (i.e.
      sirolimus and tacrolimus) will be discontinued and they will be placed on Myfortic®
      monotherapy for 2 years thereafter. After completion of two years of Myfortic® maintenance
      monotherapy, it will be weaned and subjects will be monitored over the subsequent twelve
      months, for the appearance of sensitization using panel reactive antibody (PRA) levels.
    
  